Skip to main content

Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme

Publication ,  Journal Article
Vredenburgh, J; Desjardins, A; Reardon, D
Published in: American Journal of Hematology/ Oncology
April 1, 2008

Duke Scholars

Published In

American Journal of Hematology/ Oncology

ISSN

1542-9520

Publication Date

April 1, 2008

Volume

7

Issue

4
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J., Desjardins, A., & Reardon, D. (2008). Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology, 7(4).
Vredenburgh, J., A. Desjardins, and D. Reardon. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology/ Oncology 7, no. 4 (April 1, 2008).
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology. 2008 Apr 1;7(4).
Vredenburgh, J., et al. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology/ Oncology, vol. 7, no. 4, Apr. 2008.
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology. 2008 Apr 1;7(4).

Published In

American Journal of Hematology/ Oncology

ISSN

1542-9520

Publication Date

April 1, 2008

Volume

7

Issue

4